Status:
COMPLETED
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Novartis
Conditions:
COPD
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
This study evaluated the 1 year safety, tolerability and efficacy of indacaterol against placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients
Eligibility Criteria
Inclusion
- Patients eligible to participate in the study extension, by definition, will have met the inclusion and exclusion criteria for the core 26 weeks and not met the withdrawal criteria for the core study B2335S at Visit 14 (the last visit of the core study B2335S and the first visit of the extension study B2335SE).
- In addition the following inclusion/exclusion criteria specified below must be met.
- Patients must complete Stage 2 of the core study B2335S (NCT00463567).
- Written informed consent to participate in the extension must be obtained.
- Patients must be able to comply with all study requirements.
Exclusion
- Patients who were randomized to open-label tiotropium in Study B2335S.
- Patients who participated in Stage 1 of the core study (B2335S).
- Patients discontinued irrespective of the reason from Stage 2 of the core study.
- Patients who fail to comply with the core protocol requirements and procedures.
- Concomitant medical conditions that may interfere with interpretation of study results as defined in the core study protocol.
- Patients who in the Investigator's opinion should not participate in the extension study.
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
415 Patients enrolled
Trial Details
Trial ID
NCT00677807
Start Date
May 1 2008
End Date
March 1 2009
Last Update
August 22 2011
Active Locations (190)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Homewood, Alabama, United States, 35209-6870
2
Novartis Investigative Site
Jasper, Alabama, United States, 35501
3
Novartis Investigative Site
Phoenix, Arizona, United States, 85013
4
Novartis Investigative Site
Tucson, Arizona, United States, 85712